Sunesis Pharmaceuticals Inc (SNSS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH33264D
- Pages: 58
- November 2018
- Total Views:1150
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.
Sunesis Pharmaceuticals Inc (SNSS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Equity Offering 14
Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23
Sunesis Pharma Prices Public offering of Shares for USD8 Million 25
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For USD 43 Million 26
Asset Transactions 27
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For USD 25 Million 27
Sunesis Pharmaceuticals Inc-Key Competitors 29
Sunesis Pharmaceuticals Inc-Key Employees 30
Sunesis Pharmaceuticals Inc-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights 32
Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33
May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results 35
Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights 36
Nov 02, 2017: Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights 38
Jul 27, 2017: Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights 40
May 08, 2017: Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights 42
Mar 09, 2017: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights 44
Corporate Communications 46
Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes 46
Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors 47
Dec 04, 2017: Sunesis Pharmaceuticals Announces Change in Leadership 48
Nov 30, 2017: Sunesis Pharmaceuticals Appoints William Quinn as CFO and Senior Vice President, Finance and Corporate Development 49
Legal and Regulatory 50
Jun 26, 2017: Sunesis Pharmaceuticals added to Russell Microcap Index 50
Product News 51
12/05/2017: Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 51
07/18/2017: Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies 52
Product Approvals 53
May 01, 2017: Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML 53
Mar 22, 2017: Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin 54
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062 55
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on Vosaroxin 56
Clinical Trials 57
Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List Of Figure
List of Figures
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23
Sunesis Pharma Prices Public offering of Shares for USD8 Million 25
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For USD 43 Million 26
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For USD 25 Million 27
Sunesis Pharmaceuticals Inc, Key Competitors 29
Sunesis Pharmaceuticals Inc, Key Employees 30
Sunesis Pharmaceuticals Inc, Subsidiaries 31
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Sunesis Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.
Sunesis Pharmaceuticals Inc (SNSS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Equity Offering 14
Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23
Sunesis Pharma Prices Public offering of Shares for USD8 Million 25
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For USD 43 Million 26
Asset Transactions 27
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For USD 25 Million 27
Sunesis Pharmaceuticals Inc-Key Competitors 29
Sunesis Pharmaceuticals Inc-Key Employees 30
Sunesis Pharmaceuticals Inc-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights 32
Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33
May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results 35
Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights 36
Nov 02, 2017: Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights 38
Jul 27, 2017: Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights 40
May 08, 2017: Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights 42
Mar 09, 2017: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights 44
Corporate Communications 46
Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes 46
Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors 47
Dec 04, 2017: Sunesis Pharmaceuticals Announces Change in Leadership 48
Nov 30, 2017: Sunesis Pharmaceuticals Appoints William Quinn as CFO and Senior Vice President, Finance and Corporate Development 49
Legal and Regulatory 50
Jun 26, 2017: Sunesis Pharmaceuticals added to Russell Microcap Index 50
Product News 51
12/05/2017: Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 51
07/18/2017: Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies 52
Product Approvals 53
May 01, 2017: Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML 53
Mar 22, 2017: Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin 54
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062 55
Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on Vosaroxin 56
Clinical Trials 57
Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List Of Figure
List of Figures
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sunesis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13
Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14
Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16
Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18
Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20
Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21
Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23
Sunesis Pharma Prices Public offering of Shares for USD8 Million 25
Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For USD 43 Million 26
Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For USD 25 Million 27
Sunesis Pharmaceuticals Inc, Key Competitors 29
Sunesis Pharmaceuticals Inc, Key Employees 30
Sunesis Pharmaceuticals Inc, Subsidiaries 31
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Sunesis Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020